Bavarian Nordic rapporterer toplinjeresultater fra fase 3-forsøg med COVID-19 boostervaccinekandidat
June 27, 2023 08:43 ET
|
Bavarian Nordic A/S
Boosterforsøg har succesfuldt nået sit primære mål og har vist non-inferioritet i forhold til mRNA-vaccine Vejen mod regulatorisk godkendelse vil afhænge af udfaldet af de sekundære endemål, der...
Bavarian Nordic Reports Phase 3 Topline Results for its COVID-19 Booster Vaccine Candidate
June 27, 2023 08:43 ET
|
Bavarian Nordic A/S
Booster study successfully met its primary objective, demonstrating non-inferiority to mRNA-vaccine Regulatory pathway will depend upon the outcome of secondary endpoints, reporting in the third...
Bavarian Nordic skal levere koppevacciner til strategisk lager i EU
June 23, 2023 07:47 ET
|
Bavarian Nordic A/S
KØBENHAVN, Danmark, 23. juni 2023 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at selskabet har indgået en kontrakt til en værdi af EUR 10 mio. på levering af koppevacciner til rescEU, et...
Bavarian Nordic to Supply Smallpox Vaccines for EU Strategic Reserve
June 23, 2023 07:47 ET
|
Bavarian Nordic A/S
COPENHAGEN, Denmark, June 23, 2023 – Bavarian Nordic A/S (OMX: BAVA) announced today, that it has been awarded a contract valued at EUR 10 million to supply its smallpox vaccine to rescEU, a strategic...
Bavarian Nordic rapporterer resultater fra fase 3 klinisk forsøg med VLP-baseret vaccine mod chikungunya i voksne over 65 år
June 20, 2023 02:39 ET
|
Bavarian Nordic A/S
Forsøget nåede succesfuldt sine primære endemål Resultater fra et andet afgørende fase 3 forsøg i personer i alderen 12-64 år forventes i tredje kvartal 2023 KØBENHAVN, Danmark, 20. juni 2023 –...
Bavarian Nordic Reports Data from a Phase 3 Clinical Trial of its VLP-Based Chikungunya Virus Vaccine in Adults ≥65 Years of Age
June 20, 2023 02:39 ET
|
Bavarian Nordic A/S
Study successfully met its primary endpoints Data from second pivotal Phase 3 study in people aged 12 to 64 years expected in the third quarter 2023 COPENHAGEN, Denmark, June 20, 2023 – Bavarian...
Bavarian Nordic rapporterer resultater for antistofresponser 12 måneder efter vaccination i fase 2-forsøg med COVID-19 boostervaccinekandidat
June 16, 2023 02:44 ET
|
Bavarian Nordic A/S
KØBENHAVN, Danmark, 16. juni 2023– Bavarian Nordic A/S (OMX: BAVA) rapporterede i dag resultater fra en opfølgende analyse af en delmængde af forsøgspersonerne foretaget 12 måneder efter vaccination i...
Bavarian Nordic Reports 12-Month Durability Data from a Phase 2 Clinical Trial of its COVID-19 Vaccine Candidate
June 16, 2023 02:44 ET
|
Bavarian Nordic A/S
COPENHAGEN, Denmark, June 16, 2023 – Bavarian Nordic A/S (OMX: BAVA) announced today the results of a 12-month follow-up analysis from a subset of subjects enrolled in a Phase 2 clinical trial of...
Indberetning af ledende medarbejdere og disses nærtståendes transaktioner med Bavarian Nordic aktier og tilknyttede værdipapirer
June 12, 2023 12:00 ET
|
Bavarian Nordic A/S
KØBENHAVN, Danmark, 12. juni 2023 – Bavarian Nordic A/S (OMX: BAVA) har dags dato modtaget oplysninger om følgende transaktioner med selskabets aktie/tilknyttede værdipapirer, foretaget af ledende...
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
June 12, 2023 12:00 ET
|
Bavarian Nordic A/S
COPENHAGEN, Denmark, June 12, 2023 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the company’s shares/related securities by persons holding...